# Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

> **NCT03939182** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Abexinostat
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03939182
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-29
- **Primary completion:** 2025-04-22
- **Final completion:** 2025-04-22
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03939182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03939182, "Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03939182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*